Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid, offering defensive characteristics, capital preservation, and yield over high-growth potential. The diversified product ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in a phase 3 stomach cancer trial compared to chemotherapy alone, according to ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Biotech company Amgen is investing $600 million into a new research center for its Thousand Oaks campus. The new site will create hundreds of jobs and feature advanced automation and digital ...

Amgen led four borrowers that raised $6.4bn on Monday. It was joined by Howmet Aerospace (Baa1/A-), which came to the market ...

Amgen (AMGN) has drawn fresh attention after recent trading left the shares at $379.42, capping a period in which returns ...

Slate is etching a total of $130 million into the chalkboard, money that will go toward developing next-gen headache disorder ...

LASEC and the Los Angeles World Cup 2026 Host Committee Will Collaborate with Amgen to Amplify Community Health and Legacy Programs in Greater Los Angeles Ahead of Historic Sporting Events LOS ANGELES ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.